Technical Analysis for ZIOP - ZIOPHARM Oncology Inc

Grade Last Price % Change Price Change
grade B 4.13 1.72% 0.07
ZIOP closed up 1.72 percent on Wednesday, March 20, 2019, on 1.44 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ZIOP trend table...

Date Alert Name Type % Chg
Mar 20 Spinning Top Other 0.00%
Mar 20 Upper Bollinger Band Walk Strength 0.00%
Mar 20 Wide Bands Range Expansion 0.00%
Mar 20 Above Upper BB Strength 0.00%
Mar 20 Overbought Stochastic Strength 0.00%
Mar 20 Up 3 Days in a Row Strength 0.00%
Mar 20 Up 4 Days in a Row Strength 0.00%
Mar 20 Up 5 Days in a Row Strength 0.00%
Mar 20 Upper Bollinger Band Touch Strength 0.00%
Mar 19 Pocket Pivot Bullish Swing Setup 1.72%

Older signals for ZIOP ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company's portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.
Medicine Biopharmaceutical Cancer Melanoma Cancer Therapies Metastatic Breast Cancer Metastatic Melanoma Metastatic Small Cell Lung Cancer Neoplasms
Is ZIOP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.0
52 Week Low 1.56
Average Volume 1,700,564
200-Day Moving Average 2.8205
50-Day Moving Average 2.666
20-Day Moving Average 3.2095
10-Day Moving Average 3.495
Average True Range 0.2219
ADX 42.12
+DI 43.3652
-DI 7.1224
Chandelier Exit (Long, 3 ATRs ) 3.5543
Chandelier Exit (Short, 3 ATRs ) 3.2114
Upper Bollinger Band 4.0335
Lower Bollinger Band 2.3855
Percent B (%b) 1.06
BandWidth 51.347562
MACD Line 0.3591
MACD Signal Line 0.2604
MACD Histogram 0.0987
Fundamentals Value
Market Cap 580.81 Million
Num Shares 141 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -8.26
Price-to-Sales 98.61
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.52
Resistance 3 (R3) 4.51 4.36 4.46
Resistance 2 (R2) 4.36 4.26 4.37 4.43
Resistance 1 (R1) 4.25 4.20 4.31 4.26 4.41
Pivot Point 4.10 4.10 4.13 4.11 4.10
Support 1 (S1) 3.99 4.00 4.05 4.00 3.85
Support 2 (S2) 3.84 3.94 3.85 3.83
Support 3 (S3) 3.73 3.84 3.81
Support 4 (S4) 3.74